Oncotarget published “The presence of polymorphisms in genes that control neurotransmitter metabolism and disease prognosis in prostate cancer patients: a possible link with schizophrenia” reported that polymorphisms in neurotransmitter metabolism genes were studied in patients with prostate cancer (PC) characterized by reduced serum or extensive prostate-specific antigen duplication time corresponding to unfavorable and favorable disease prognosis respectively.
The following gene polymorphisms known to be associated with neuropsychiatric disorders were investigated:
- A. The STN2 VNTR in the serotonin transporter gene SLC6A4;
- B. The 30 bp VNTR in the MAOA gene of monoamine oxidase A;
- C. The Val158Met polymorphism in the COMT gene of catechol-ortho-methyltransferase;
- D. Polymorphism of the C-521T promoter region and 48 VNTR in the third exon of the dopamine receptor DRD4 gene.
The STin2 12R / 10R variant of the SLC6A4 gene and the -521T / T homozygosity of the DRD4 gene used to be over-represented in PC patients with an unfavorable disease prognosis.
These gene variants are considered protective against schizophrenia, and the observed trend may be directly related to a reduced risk of PC described for patients with schizophrenia.
These results justify a more detailed investigation of the potential role of gene polymorphisms in neurotransmitter metabolism in the pathogenesis of PC.
Dr. Vladimir N. Anisimov, of the Petrov National Medical Research Oncology Center, said: “The importance of complex networks of heterotypic interactions between multiple different cell types (both malignant and normal) and regulatory circuits has been widely recognized “.
The traditional tumor-centered view focused exclusively on malignant cell populations has been largely replaced by a concept of tumor microenvironment, the latter being seen as a “arena of dynamic interaction in which tumor cells they interact with the extracellular matrix, resident and recruited cells, and soluble factors. “
Although there is a general consensus that chronic stress and depression tend to cause a deterioration in immune responses and can facilitate the onset and progression of cancer, while the risk of developing some types of cancer appears to decrease. in patients with schizophrenia.
Pancreatic cancer is not only the second most common cancer in men, but it is also a condition characterized by a wide variation in severity ranging from indolent to very aggressive disease.
This latest feature of the PC brand tumor growth Monitoring a very important prerequisite for successful disease management and repeated measurement of the concentration of a PC blood biomarker, a prostate-specific antigen, is generally accepted as an important prognostic tool for routinely monitor patients with this condition.
It was noted above that psychiatric disorders may be associated with a severely altered risk of PC, but little is known about the possible influences of patients’ genetic background on both this phenomenon and the prognosis of the disease when PC is already present. .
Anisimov’s research team concluded in his Oncotarget Research shows that oncological conditions occur less frequently in patients with schizophrenia, and that this phenomenon mainly affects men, being especially pronounced for PC.
Interestingly, PC has recently emerged as a cancer, the development of which depends largely on the neurogenic regulatory pathways provided by nerves that grow as an important TME component.
In addition, neurotransmitters, such as serotonin and dopamine, are now considered the major factors modulating neoplastic growth through influences on angiogenesis and neoplastic cell proliferation.
The results presented in this article indicate that the presence of certain polymorphic variants of SLC6A4 and DRD4 people related to serotonin and dopamine signaling pathways, respectively, appear to correlate with the prognosis of PC.
Extensive studies are needed to clarify the role of gene polymorphisms in neurotransmitter metabolism in the pathogenesis of PC.
Gennady M. Zharinov et al, The presence of polymorphisms in genes that control neurotransmitter metabolism and disease prognosis in patients with prostate cancer: a possible link with schizophrenia, Oncotarget (2021). DOI: 10.18632 / oncotarget.27921
Provided by Impact Journals LLC
Citation: Prostate Cancer and a Possible Link to Schizophrenia (2021, June 11) Retrieved June 11, 2021 at https://medicalxpress.com/news/2021-06-prostate-cancer-link-schizophrenia. html
This document is subject to copyright. Apart from any fair treatment for the purposes of private study or research, no part may be reproduced without written permission. Content is provided for informational purposes only.